Substance Use Disorders

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Substance Use Disorders is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed6 · 60%

Recruiting3 · 30%

Enrolling by invitation1 · 10%

Clinical Trials

Trial Activity

10 trials

Culturally Engaged REcovery - MOms Connected Through Native communitY (CEREMONY)

Recruiting·UUniversity of Utah·Preclinical·NCT06747442·270 enrolled

Comparing Treatment Use, Retention, and Patient Outcomes Pre- and Post-implementation of Federal Policy Changes Regulating Buprenorphine and Methadone Treatment for Opioid Use Disorder

Recruiting·BBoston University·N/A·NCT07232641·185,810 enrolled

STOP (Shared Decision Making to Treat Or Prevent) HIV in Criminal Legal Involved Populations

Recruiting·YYale University·Preclinical·NCT07223398·400 enrolled

Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl

Enrolling by invitation·National Institute on Drug Abuse (NIDA)·N/A·NCT06995885·30 enrolled

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

Completed·—·N/A·NCT00756275·158 enrolled

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

Completed·—·Phase 4·NCT02845453·24 enrolled

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Completed·—·Phase 2·NCT02742532·63 enrolled

Medication-Assisted Treatment for Youth With Substance Use Disorders

Completed·NNew York State Psychiatric Institute·Phase 1·NCT02593474·11 enrolled

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Completed·MMedical University of South Carolina·Phase 1·NCT02058251·73 enrolled

Characterization of Phenotypic and Genotypic Regressors

Completed·National Institute on Drug Abuse (NIDA)·N/A·NCT01148381·847 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)